Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Around 28% of the eligible population has taken the first booster dose of the Covid-19 vaccine so far.

Covid: talks on allowing second booster dose in India begin among vaccine experts in govt panel NTAGI

Around 28% of the eligible population has taken the first booster dose of the Covid-19 vaccine so far.

Amid concerns over a possible Covid wave in India, the country's expert panel on immunisation is discussing the possibility of allowing a second booster dose to people, according to a Hindustan Times report.
A member of the National Technical Advisory Group on Immunisation (NTAGI) said that a section supports a second booster dose, but all scientific data will be minutely studied before any recommendation to the government.
Around 28% of the eligible population has taken the first booster dose of the Covid-19 vaccine so far.
The Narendra Modi government recently approved the country's first intranasal vaccine as a booster. Bharat Biotech's iNCOVACC's approval for emergency use among adults who have received two doses of Covishield or Covaxin vaccine coincided with the surge of cases in neighbouring China.
Also watch: <a href="https://www.editorji.com/india-news/indigo-plane-suffers-technical-glitch-forced-to-abandon-phuket-journey-return-to-delhi-1672725203558">IndiGo plane suffers technical glitch, forced to abandon Phuket journey, return to Delhi</a>

While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin

Watch how many crore vaccine doses Indian firms Bharat Biotech, Biological E have ready now | Covid

While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin

Amid the sounding of a Covid alert in India, domestic vaccine-makers Bharat Biotech and Biological E Ltd are sitting on a stockpile of 25 crore doses.
While Biological E has a stock of 20 crore doses of its vaccine Corbevax, Bharat Biotech has 5 crore doses ready of Covaxin. This was reported by news agency PTI quoting company officials.
The vaccines are ready to be dispatched.
This comes even as the Union government has cleared Bharat Biotech's nasal vaccine iNCOVACC as a booster dose.
Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government.
In March 2022, Biological E successfully supplied 10 crore doses to the government.
"Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar told PTI.
Also read|<a href="https://www.editorji.com/india-news/india-nasal-vaccine-price-revealed-800-plus-5-gst-for-bharat-biotech-s-incovacc-says-report-1672121485100">India nasal vaccine price: ₹800 at private, ₹325 in govt hospitals, GST extra for Bharat Biotech iNCOVACC</a>
(With PTI inputs)

The Narendra Modi administration recently filed an affidavit in response to a petition filed by the parents of two young women who died after getting Covid vaccines in 2021.

Cannot hold govt liable for deaths due to Covid vaccine side-effects: Centre to Supreme Court

The Narendra Modi administration recently filed an affidavit in response to a petition filed by the parents of two young women who died after getting Covid vaccines in 2021.

Almost two years after India rolled out the "world's largest" immunisation programme against Covid, the Union government has said that it is not liable to provide compensation for deaths due to vaccine side-effects, according to a Hindustan Times report.
The Narendra Modi administration recently filed an affidavit in response to a petition filed by the parents of two young women who died after getting Covid vaccines in 2021.
Also read|<a style="color: rgb(53, 152, 219);" href="https://www.editorji.com/india-news/spike-in-measles-cases-in-mumbai-one-year-old-girl-dies-1669684420236">Spike in Measles cases in Mumbai, one-year-old girl dies</a>
The petition had sought an independent investigation into the deaths, formulation of a protocol for early detection and timely treatment of adverse effects following immunization (AEFI).
The government said that holding the state responsible for "extremely rare deaths" due to vaccine side-effects "may not be legally sustainable". The government added that in cases where death is caused by vaccines, the only remedy is seeking compensation through civil courts.

China finally started giving nasal covid shots to its citizens on Wednesday. The vaccine has passed clinical trials in China, Hungary, Pakistan, Malaysia, Argentina and Mexico.

China becomes first to roll-out 'needle-free' Covid vaccine which is inhaled through mouth

After slowly inhaling, people are supposed to hold their breath for five seconds, and the entire procedure concludes in around 20 seconds.

China has started administering Covid vaccines which are inhaled through the mouth. This is possibly the world's first roll-out of an inhalable Covid vaccine.
The vaccine is in the form of a mist that is sucked in through the mouth. After slowly inhaling, people are supposed to hold their breath for five seconds, and the entire procedure concludes in around 20 seconds.
One recipient was quoted as saying that the vaccine tasted "a bit sweet", and it was like "drinking a cup of milk tea". The vaccine is being offered for free as a booster dose for previously vaccinated people in the Chinese city of Shanghai.
It was developed by Chinese biopharmaceutical company CanSino Biologics Inc. Chinese regulators approved the vaccine for use as a booster in September 2022.
Such 'needle-free' vaccines are expected to help increase vaccination rates. These would be more accessible in countries with fragile health systems as they are easier to administer. Also, people who don't like getting a shot in the arm would be willing to get inoculated through inhalable vaccines.
Regulators in India have approved a nasal vaccine which is squirted in the nose, but it has yet to be rolled out. The vaccine was developed in the US and licensed to Indian vaccine-manufacturer Bharat Biotech.
(With PTI inputs)

He said that the vaccine manufacturer stopped the production of Covishield vaccine in December 2021, and of the total stock available at that time, around 100 million doses have already expired.

'People are fed up of Covid': Adar Poonawalla on low demand for vaccines

Adar Poonwalla, the Chief Executive Officer of Serum Institute of India, has said that booster shots for novel coronavirus have no demand at the moment as people are fed of Covid and vaccines.

'People are fed up of Covid': Adar Poonawalla on low demand for boosters

He said that the vaccine manufacturer stopped the production of Covishield vaccine in December 2021, and of the total stock available at that time, around 100 million doses have already expired.

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Thursday said the vaccine manufacturer stopped the production of Covishield vaccine starting December 2021, and of the total stock available at that time, around 100 million doses had already got expired.
Speaking to reporters on the sidelines of the annual general meeting of Developing Countries Vaccine Manufacturers Network (DCVMN), he said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.
"Since December 2021, we stopped the production (of Covishield). We had a stock of a few hundred million doses at that time and of that, 100 million doses have already expired," said Poonawalla when asked about the update on the Covishield vaccine.
He said the SII's vaccines are allowed to be mixed.
"Now, Covovax should be allowed in two weeks. So I think they will and should probably have the policy to mix boosters. If WHO allowed it, then maybe the Indian regulator will and should allow it. But again, boosters have no demand at the moment. There is lethargy generally. People are fed up of COVID, vaccines. To be honest, I am also fed up with it. We all are," he said.
Also watch: <a href="https://www.editorji.com/india-news/local/up-dengue-patient-transfused-with-fruit-juice-instead-of-platelets-died-later-claim-relatives-1666317425956">UP: dengue patient transfused with fruit juice instead of platelets, died later, claim relatives</a>
Going forward, when people take a few shots every year, they may take anti-coronavirus vaccines and other shots together, Poonawalla said, adding, "It will become that kind of a product." "In India, there is no culture of taking flu shots as we see it in the West. We tried when we launched a few vaccines in 2010. During the H1NI pandemic in 2011, no one took it. Flu is not something that sounds scary to people. They just do not want to take it," he said.
Covishield was produced at the SII's Pune facility with a master seed from Oxford University and AstraZeneca. The SII had announced its partnership with Oxford University to manufacture the vaccine in April 2020.&nbsp;

Holding out the promise of preventing even mild infections and blocking transmission, mucosal vaccines may well be a game changer for the Covid pandemic, say scientists as Indians gear up for the world’s first intranasal preventive.
A nasal, non-invasive and cheaper alternative to injectable vaccines could be just what is needed in a world battling a waning and waxing Covid wave with new variants throwing up challenges at every step, the experts said.
Earlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world’s first intranasal COVID-19 vaccine, has received approval from the Drugs Controller General of India for restricted use in emergencies for those 18 and older. The vaccine is yet to be marketed.
By prompting an immune response where the virus first enters the body, researchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people, something current COVID-19 shots are unable to do. “This pandemic has been dragging on because new variants continue to emerge that are capable of causing a lot of infections and transmission among people who were already vaccinated,” said David T. Curiel, a professor at Washington University.
“A nasal vaccine may be what we need to finally break the cycle of transmission," Curiel said in a statement.
Immunologist Vineeta Bal agreed, explaining that intranasal vaccines are supposed to produce antibodies locally, i.e. in the upper respiratory passage, the entry point for SARS-CoV2.
Because of their presence, the virus is supposed to be 'neutralised' immediately after entry without letting it gain a foothold by entry in the cells and reproducing.
"This means early clearance of the virus from the body before its spread to lungs and other organs is a distinct possibility and an advantage over other intramuscular injectable vaccines," Bal, from Pune’s Indian Institute of Science Education and Research (IISER), said.
"Because the infection is 'nipped in the bud' so to say, viral replication inside the host body is less," she explained.
India is not the only country to have approved a mucosal COVID-19 vaccine. China did too. However, while China’s mucosal vaccine is inhaled through the nose and mouth, India's intranasal coronavirus vaccine is administered as drops in the nose.
Bharat Biotech has said its BBV154 vaccine is proven to be safe and generated an immune response in clinical trials on about 4,000 volunteers.
Mucosal vaccines target thin membranes that line the nose, mouth and lungs. They are administered by contact with linings of the body's barrier organs through drops, sprays, or swallowed capsules.
BBV154 is made from adenovirus, a relative in the family of cold viruses that expresses the spike protein found in SARS-CoV-2, which the virus uses to enter and infect the cells.
"There are two advantages of intranasal vaccines over intramuscular (or subcutaneous) vaccines," said immunologist Satyajit Rath, also from IISER.
"One thing is clear; they are easier to administer, since they do not need to be injected. The second one, which is being widely discussed, is more hypothetical -- they are thought to provide better immediate local protection in the lining of nose, throat and large lung airways," Rath told PTI.
While there is some evidence, mostly from polio vaccines, for this advantage of the mucosal vaccines, it is not yet clear if they will live up to this in actual usage in people, he explained.
Bal added that the ease of use of the intranasal vaccine makes it easier to administer on a mass scale.
"Oral polio vaccine is the case in point. Only because needle syringes are avoided, the fear in people's minds also can be less," Bal told PTI.
"However, how uniformly the predetermined volume of the vaccine can be given and whether optimal amount of virus will trigger immune response are some of the variables to be kept in mind," she added.
Another plus point for a nasal vaccine is the cost factor. Though the pricing for Bharat Biotech’s intranasal vaccine is still unclear, it will be considerably cheaper than the injectable ones.
The nasal delivery system was designed and developed to be cost-effective, a feature that is especially important in low- and middle-income countries, and the vaccine can be stored in a refrigerator, scientists said.
Receiving the vaccine requires only a brief inhalation, a major advantage for the many people who prefer to avoid needles, according to researchers at Washington University, which developed the vaccine technology on which BBV154 is based.
Importantly, they said, the design of the vaccine makes it relatively quick and easy to update when new variants emerge -- simply by switching out the current spike protein with one from a new variant.
In a study published in July, the researchers also noted that intranasal vaccines for COVID-19 will be critical to protect people against the emerging variants of concern.
“The nasal vaccine provides a mucosal antigen boost to the pre-existing immune cells that direct immune response, resulting in higher immunity,” they explained.
Rath cautioned that the possible emergence of yet another virus variant that can efficiently avoid the current immune responses could well change everything.
"There is yet no evidence indicating that such mucosal vaccines will have any unique utility specifically against new SARS-CoV-2 variants," he said.
However, Rath noted that if such vaccines reduce infection, rather than reducing illness severity, they will be helpful in maintaining control over rates of virus transmission.
Four mucosal vaccines for COVID-19 in the world have been approved so far, including one each in Iran and Russia, according to Airfinity, a London-based health-analytics company.
Over 100 mucosal vaccines against the disease are in development worldwide, and about 20 have reached human clinical trials, it said.
In principle, according to Bal, highly immunogenic nasal vaccines can significantly decrease the efficacy of transmission.
"Our reluctance to use masks can be partly compensated by a very effective nasal vaccine. Based on the data... if this is really the case, then nasal vaccines would be useful as boosters as well," Bal said.
She said India's nasal vaccine has been given permission as a primary vaccine and not as a booster. That means its utility with the present approval is very very limited in India.
"However, globally, especially in many other lower and middle-income countries (LMICs) there is still very poor vaccine coverage and this vaccine might find a place in such countries," Bal added.
India logged 4,369 new coronavirus infections, according to the Union Health Ministry on Tuesday, the lowest in over three months. However, the threat of another variant is ever present

Explained: why scientists think nasal Covid vaccines will be a gamechanger

India origin Bharat Biotech announced that its INCOVACC (BBV154), the world’s first intranasal COVID-19 vaccine, has received approval from the Drugs Controller General of India for restricted use in emergencies for those 18 and older.  

A nasal, non-invasive and cheaper alternative to injectable vaccines could be just what is needed in a world battling a waning and waxing Covid wave with new variants throwing up challenges at every step.

Holding out the promise of preventing even mild infections and blocking transmission, mucosal vaccines may well be a game changer for the Covid pandemic, say scientists as Indians gear up for the world&rsquo;s first intranasal preventive.
A nasal, non-invasive and cheaper alternative to injectable vaccines could be just what is needed in a world battling a waning and waxing Covid wave with new variants throwing up challenges at every step, the experts said.
Earlier this month, Bharat Biotech announced that its iNCOVACC (BBV154),the world&rsquo;s first intranasal COVID-19 vaccine, has received approval from the Drugs Controller General of India for restricted use in emergencies for those 18 and older. The vaccine is yet to be marketed.
By prompting an immune response where the virus first enters the body, researchers believe mucosal vaccines may prevent even mild cases of illness and block transmission to other people, something current COVID-19 shots are unable to do.
&ldquo;This pandemic has been dragging on because new variants continue to emerge that are capable of causing a lot of infections and transmission among people who were already vaccinated,&rdquo; said David T. Curiel, a professor at Washington University.
&ldquo;A nasal vaccine may be what we need to finally break the cycle of transmission," Curiel said in a statement.
Immunologist Vineeta Bal agreed, explaining that intranasal vaccines are supposed to produce antibodies locally, i.e. in the upper respiratory passage, the entry point for SARS-CoV2.
Because of their presence, the virus is supposed to be 'neutralised' immediately after entry without letting it gain a foothold by entry in the cells and reproducing.
"This means early clearance of the virus from the body before its spread to lungs and other organs is a distinct possibility and an advantage over other intramuscular injectable vaccines," Bal, from Pune&rsquo;s Indian Institute of Science Education and Research (IISER), said.
"Because the infection is 'nipped in the bud' so to say, viral replication inside the host body is less," she explained.
India is not the only country to have approved a mucosal COVID-19 vaccine. China did too. However, while China&rsquo;s mucosal vaccine is inhaled through the nose and mouth, India's intranasal coronavirus vaccine is administered as drops in the nose.
Also Watch| <a href="https://www.editorji.com/world-news/scientists-develop-eco-friendly-plastic-film-that-can-kill-the-sars-cov-2-virus-1663144406986">Scientists develop eco-friendly plastic film that can kill the SARS-CoV-2 virus</a>
Bharat Biotech has said its BBV154 vaccine is proven to be safe and generated an immune response in clinical trials on about 4,000 volunteers.
Mucosal vaccines target thin membranes that line the nose, mouth and lungs. They are administered by contact with linings of the body's barrier organs through drops, sprays, or swallowed capsules.
BBV154 is made from adenovirus, a relative in the family of cold viruses that expresses the spike protein found in SARS-CoV-2, which the virus uses to enter and infect the cells.
"There are two advantages of intranasal vaccines over intramuscular (or subcutaneous) vaccines," said immunologist Satyajit Rath, also from IISER.
"One thing is clear; they are easier to administer, since they do not need to be injected. The second one, which is being widely discussed, is more hypothetical -- they are thought to provide better immediate local protection in the lining of nose, throat and large lung airways," Rath told PTI.
While there is some evidence, mostly from polio vaccines, for this advantage of the mucosal vaccines, it is not yet clear if they will live up to this in actual usage in people, he explained.
Bal added that the ease of use of the intranasal vaccine makes it easier to administer on a mass scale.
"Oral polio vaccine is the case in point. Only because needle syringes are avoided, the fear in people's minds also can be less," Bal told PTI.
"However, how uniformly the predetermined volume of the vaccine can be given and whether optimal amount of virus will trigger immune response are some of the variables to be kept in mind," she added.
Another plus point for a nasal vaccine is the cost factor. Though the pricing for Bharat Biotech&rsquo;s intranasal vaccine is still unclear, it will be considerably cheaper than the injectable ones.
The nasal delivery system was designed and developed to be cost-effective, a feature that is especially important in low- and middle-income countries, and the vaccine can be stored in a refrigerator, scientists said.

China has approved the world's first inhaled version of Covid-19 vaccine. Now people can get themselves vaccinated without bearing the pain of a needle. The new vaccine will pave the way for the potential use of needle-free product in the country.
The vaccine has been approved for emergency use as a booster dose by China's medicines regulator. 
Vaccine maker 'CanSino Biologics' which has named the product Convidecia air said the vaccine dose in inoculated through a puff of air from a nebulizer, and is inhaled by mouth.
The World Health Organization in a report stated that CanSino's new product is one of the two specifically 'inhaled' vaccines to have reached clinical phase development, as a number of firms worldwide research ways to protect to shield from Covid-19 vaccine via the nouse and mouth.
Meanwhile, India too has launched a needle free vaccine bu launching its very first nasal vaccine manufactured by Bharat Biotech after approval by Drugs Controller General of India 

China approves world's first inhaler Covid-19 vaccine

CanSino's new product is one of the two specifically 'inhaled' vaccines. Several experts worldwide are looking into new ways to shield people from Covid-19 vaccine.

CanSino's new product is one of the two specifically 'inhaled' vaccines. Several experts worldwide are looking into new ways to shield people from Covid-19 vaccine.

China has approved the world's first inhaled version of Covid-19 vaccine. Now people can get themselves vaccinated without bearing the pain of a needle. The new vaccine will pave the way for the potential use of needle-free product in the country.
The vaccine has been approved for emergency use as a booster dose by China's medicines regulator.&nbsp;
Vaccine maker 'CanSino Biologics' which has named the product 'Convidecia Air' said the vaccine dose is turned into mist by a nebuliser that is then inhaled by mouth.
The World Health Organization in a report stated that CanSino's new product is one of the two specifically 'inhaled' vaccines which have reached clinical phase development.&nbsp; It added that several firms worldwide are researching ways to shield people from Covid-19 vaccine via nouse and mouth.
Meanwhile, India too has approved a needle free vaccine. A nasal dose developed by Bharat Biotech has been granted approval by the drug regulator for restricted emergency use in adults.&nbsp;

Eighteen months after launching the nationwide Covid vaccination drive, India crossed a major milestone - that of administering over 200 crore vaccines.
The vaccination drive began on 16 January 2021. India had crossed the 100-crore milestone 277 days after launching of the drive. The highest single-day tally of jabs has been 2.5 crore on 17 September 2021.
Reacting to the development, Prime Minister Narendra Modi said that India had created history again. The PM congratulated the nation, while expressing pride in those who contributed to making the vaccination drive "unparalleled in scale and speed". Modi added that throughout the process, Indians showed "remarkable faith in science".
Union Health Minister Mansukh Mandaviya called the vaccination journey a "mighty epitome of Sabka Prayas", which is a part of the Modi government's motto of "Sabka Saath, Sabka Vikas, Sabka Vishwas, Sabka Prayaas".
India currently has over 1.4 lakh active cases, with more than 20,500 new cases being recorded between 16 and 17 July.

India crosses mega 200-crore Covid vaccine milestone

India crosses 200-crore Covid vaccine milestone Over 200 crore Covid jabs administered in India India's Covid vaccine drive began on 16 Jan 2021

Reacting to the development, Prime Minister Narendra Modi said that India had created history again.

Eighteen months after launching the nationwide Covid vaccination drive, India crossed a major milestone - that of administering over 200 crore vaccines.
The vaccination drive began on 16 January 2021. India had crossed the 100-crore milestone 277 days after launching of the drive. The highest single-day tally of jabs has been 2.5 crore on 17 September 2021.
Reacting to the development, Prime Minister Narendra Modi said that India had created history again. The PM congratulated the nation, while expressing pride in those who contributed to making the vaccination drive "unparalleled in scale and speed". Modi added that throughout the process, Indians showed "remarkable faith in science".
Union Health Minister Mansukh Mandaviya called the vaccination journey a "mighty epitome of Sabka Prayas", which is a part of the Modi government's motto of "Sabka Saath, Sabka Vikas, Sabka Vishwas, Sabka Prayaas".
Also watch: <a href="https://www.editorji.com/coronavirus/free-covid-precaution-doses-for-18-59-age-group-from-july-15-at-govt-centres-1657725280583" target="_blank">Free Covid precaution doses for 18-59 age group from July 15 at govt centres</a>
India currently has over 1.4 lakh active cases, with more than 20,500 new cases being recorded between 16 and 17 July.

The gap between the second dose of Covid-19 vaccine and the precaution has been reduced to 6 months from 9. 
A notification issued by the government said it was bringing down the gap in view of evolving scientific evidence and global practices. 
Covid-10 precaution is currently available for anyone who is 18 years or above. 
India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10. 
On April 10, India began administering precaution doses of COVID-19 vaccines to all aged above 18.

Govt reduces gap for Covid booster dose to 6 months

The gap between the second dose of Covid-19 vaccine and the precaution has been reduced to 6 months from 9. 

India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.&nbsp;

The gap between the second dose of Covid-19 vaccine and the precaution has been reduced to 6 from 9 months&nbsp;.&nbsp;
A notification issued by the government said it was bringing down the gap in view of evolving scientific evidence and global practices.&nbsp;
Covid-19 precaution is currently available for anyone who is 18 years or above.&nbsp;
India began administering precaution doses of vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10.&nbsp;
On April 10, India began administering precaution doses of COVID-19 vaccines to all aged above 18.

Developed by the Haryana-based ICAR-National Research Centre on Equines, India has got its first homemade Covid-19 vaccine for animals called Anocovax.The immunity induced by Anocovax neutralises both Delta and Omicron variants of coronavirus, the Indian Council of Agricultural Research said in a statement.
The vaccine contains inactivated Delta antigen with Alhydrogel as an adjuvant. It is safe for dogs, lions, leopards, mice and rabbits.
 

Anocovax: India's first Covid vaccine for animals launched

The immunity induced by Anocovax neutralises both Delta and Omicron variants of coronavirus, the Indian Council of Agricultural Research said in a statement.

Developed by the Haryana-based ICAR-National Research Centre on Equines, India has got its&nbsp;first homemade&nbsp;Covid-19 vaccine for animals called Anocovax.
Agriculture Minister Narendra Singh Tomar on Thursday launched the country's first homegrown COVID-19 vaccine Anocovax for animals, developed by Haryana-based ICAR-National Research Centre on Equines (NRC).
Anocovax is an inactivated SARS-CoV-2 Delta (COVID-19) vaccine for animals. The immunity induced by Anocovax neutralises both Delta and Omicron variants of SARS-CoV-2, the Indian Council of Agricultural Research (ICAR) said in a statement.
The vaccine contains inactivated SARS-CoV-2 (Delta) antigen with Alhydrogel as an adjuvant. It is safe for dogs, lions, leopards, mice and rabbits, it added.
"It is due to the untiring contributions of scientists that the country stands self-reliant in developing its own vaccines more rather than importing. This is really a big achievement," Tomar said after the virtual launch of the COVID-19 vaccine and diagnostic kits for animals developed by the ICAR-NRC.
Besides Anocovac, Tomar launched the 'CAN-CoV-2 ELISA kit' -- a sensitive and specific nucleocapsid protein-based indirect ELISA kit -- for antibody detection against SARS-CoV-2 in canines.
"There are no laboratory animals required for the preparation of the antigens. The kit is made in India and a patent has been filed for the same. No other comparable kits for detection of antibodies in canines are available in the market," the ICAR said.
Surra ELISA kit, a suitable diagnostic assay for 'Trypanosoma evansi' infection in multiple animal species, was also launched.
Surra is one of the most important haemoprotozoan diseases of the different livestock species caused by Trypanosoma evansi. The disease is prevalent in all the agro-climatic parts of India. In India, losses to livestock productivity were estimated to be Rs 44,740 million annually due to Surra, the ICAR noted. Also watch: <a href="https://www.editorji.com/sports-news/cricket/kane-williamson-ruled-out-of-2nd-test-vs-england-after-testing-covid-19-positive-1654851095648">Kane Williamson ruled out of 2nd Test vs England after testing Covid-19 positive</a>
The minister also launched the Equine DNA parentage testing kit, which is a powerful genomic technology for parentage analysis among horses.
ICAR Director General Trilochan Mohapatra, Animal Husbandry and Dairying Secretary Atul Chaturvedi, and ICAR Deputy Director General (Animal Science) Bhupendra Nath Tripathi were also present.
ICAR is the country's premier agri-research institute that functions under the Union Agriculture Ministry.&nbsp;

Relaxing norms for Covid vaccine precaution dose, the Centre on Thursday allowed citizens travelling overseas to get the shot before the stipulated nine-month waiting period as required by the guidelines of the destination country
The Union Health Ministry's decision to relax the norms about the precaution dose for overseas travellers was based on recommendations by the National Technical Advisory Group on Immunisation (NTAGI).
"Indian citizens and students travelling overseas can now take the precaution dose as required by the guidelines of the destination country. This new facility will be available soon on the CoWIN portal," Union Health Minister Mansukh Mandaviya said in a tweet.
The advisory panel last week had recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to before the mandatory nine-month gap.
Currently, all those above 18 years who have completed nine months after the second dose are eligible for the precaution jab.
The ministry had received several representations seeking the precaution dose of Covid vaccine for those who have to travel abroad for employment, business commitments, admission to foreign educational institutes, participating in sports events, and bilateral and multilateral meetings as part of India's official delegation.
"The issue was discussed in a meeting of NTAGI held last week after which it recommended that those who need to travel overseas can take the booster shot, before the stipulated nine-month waiting period, as per the booster guidelines of the country they are travelling to," a source had said.
India began administering precaution doses of Covid vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10 this year.
The comorbidity clause was removed in March making all people aged above 60 eligible for the precaution dose of Covid vaccine.
On April 10, India began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres. 

Travelling aboard? You can now take Covid-19 precaution dose before 9 months

Modi govt allows Indians travelling abroad to take Covid-19 booster dose before 9-month waiting period

Relaxing norms for Covid vaccine precaution dose, the Centre on Thursday allowed citizens travelling overseas&nbsp;to get the shot before the stipulated nine-month waiting period

Relaxing norms for Covid vaccine precaution dose, the Centre on Thursday allowed citizens travelling overseas&nbsp;to get the shot before the stipulated nine-month waiting period as required&nbsp;by the guidelines of the destination country
The Union Health Ministry's decision to relax the norms about the precaution dose for overseas travellers was based on recommendations by the National Technical Advisory Group on Immunisation (NTAGI).
"Indian citizens and students travelling overseas can now take the precaution dose as required by the guidelines of the destination country. This new facility will be available soon on the CoWIN portal," Union Health Minister Mansukh Mandaviya said in a tweet.
The advisory panel last week had recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to before the mandatory nine-month gap.
Currently, all those above 18 years who have completed nine months after the second dose are eligible for the precaution jab.
The ministry had received several representations seeking the precaution dose of Covid vaccine for those who have to travel abroad for employment, business commitments, admission to foreign educational institutes, participating in sports events, and bilateral and multilateral meetings as part of India's official delegation.
"The issue was discussed in a meeting of&nbsp;NTAGI held last week after which it recommended that those who need to travel overseas can take the booster shot, before the stipulated nine-month waiting period, as per the booster guidelines of the country they are travelling to," a source had said.
India began administering precaution doses of Covid vaccines to healthcare and frontline workers and those aged 60 and above with comorbidities from January 10 this year.
Also watch:&nbsp;<a href="https://www.editorji.com/coronavirus/sc-nobody-can-be-forced-to-undergo-vaccinations-covid-19-1651471087521">SC: nobody can be forced to undergo vaccinations | Covid-19</a>
The comorbidity clause was removed in March making all people aged above 60 eligible for the precaution dose of Covid vaccine.
On April 10, India began administering precaution doses of COVID-19 vaccines to all aged above 18 years at private vaccination centres.&nbsp;

At this year's Met Gala, India was represented by businesswoman Natasha Poonawalla. The executive director of vaccine production company Serum Institute of India wore a dress by designer Sabyasachi.
Describing her dress, Natasha, who is married to SII CEO Adar Poonawalla said that the 2022 Met Gala had a "prescient theme" in 'Gilded Glamour' which "resonates more strongly today than ever before".
Natasha added, "On the one hand, we see astronomical progress — to the degree that we’ve conquered space — and on the other hand we’re quick to police women or the vulnerable among us, their bodies, their choices, and their opportunities. It’s a bit like the golden cage."

Met Gala 2022: Indian vaccine firm Serum Institute of India's Natasha Poonawalla sole Indian at mega New York event

Met Gala: Serum Institute's Natasha Poonawalla sole Indian at mega New York event


THUMBNAIL INDIAN VACCINE FIRM'S EXEC DIR AT MET GALA
&nbsp;
&nbsp;
((VISUALS))
https://twitter.com/NPoonawalla/status/1521546105795788800
&nbsp; https://twitter.com/NPoonawalla/status/1521541357248163840
&nbsp;
At this year's Met Gala, India was represented by businesswoman Natasha Poonawalla. The executive director of vaccine production company Serum Institute of India wore a dress by designer Sabyasachi. Describing her dress, Natasha, who is married to SII CEO Adar Poonawalla said that the 2022 Met Gala had a "prescient theme" in 'Gilded Glamour' which "resonates more strongly today than ever before". Natasha added that on the one hand, we see astronomical progress &mdash; to the degree that we&rsquo;ve conquered space &mdash; and on the other hand we&rsquo;re quick to police women or the vulnerable among us, their bodies, their choices, and their opportunities. "It&rsquo;s a bit like the golden cage", she said.

Natasha Poonawalla, executive director of SII&nbsp;attended the Met Gala in New York

At this year's Met Gala, India was represented by businesswoman Natasha Poonawalla. The executive director of vaccine production company Serum Institute of India wore a dress by designer Sabyasachi.
Describing her dress, Natasha, who is married to SII CEO Adar Poonawalla said that the 2022 Met Gala had a "prescient theme" in 'Gilded Glamour' which "resonates more strongly today than ever before".
Natasha added, "On the one hand, we see astronomical progress &mdash; to the degree that we&rsquo;ve conquered space &mdash; and on the other hand we&rsquo;re quick to police women or the vulnerable among us, their bodies, their choices, and their opportunities. It&rsquo;s a bit like the golden cage."
Also Watch|&nbsp;<a href="https://www.editorji.com/entertainment-news/hollywood/met-gala-2022-blake-lively-sophie-turner-billie-eilish-and-others-stun-at-red-carpet-1651571237188" target="_blank">Met Gala 2022: Blake Lively, Sophie Turner, Billie Eilish and others stun at red carpet</a> &nbsp;

A woman in Spain caught Covid twice, within 20 days, and with different variants. This is being pegged as the shortest re-infection gap recorded since the beginning of the Covid-19 pandemic.
The patient is a healthcare worker, who was fully vaccinated, and had even received a booster dose. Just 12 days after the booster vaccine, on December 20, 2021, the woman tested positive during a staff screening test. She went into isolation for 10 days, but did not develop any symptoms.
Then, on January 10, 2022, twenty days after the first infection, she developed Covid-like symptoms and took another RT-PCR test.The result again came out to be positive.
When the samples were sent for genome sequencing, it emerged that the woman had been infected by two different variants of the Sars-CoV-2 virus. The first, symptom-less infection was with the Delta variant, while the second one was Omicron, with cough and fever.
Scientists said that this case shows how Omicron can evade immunity from both vaccines and previous infections.

Woman gets Covid twice in 20 days, with 2 different variants, Delta and Omicron: shortest infection gap. Watch details

Spain woman gets Covid twice in 20 days, with 2 different variants. Shortest re-infection gap so far, say scientists. Watch details

Woman gets Covid twice in 20 days, with 2 different variants: shortest re-infection gap. Watch details

A woman in Spain caught Covid twice, within 20 days, and with different variants. This is being pegged as the shortest re-infection gap recorded since the beginning of the Covid-19 pandemic. The patient is a healthcare worker, who was fully vaccinated, and had even received a booster dose. Just 12 days after the booster vaccine, on December 20, 2021, the woman tested positive during a staff screening test. She went into isolation for 10 days, but did not develop any symptoms. Then, on January 10, 2022, twenty days after the first infection, she developed Covid-like symptoms and took another RT-PCR test. The result again came out to be positive. When the samples were sent for genome sequencing, it emerged that the woman had been infected by two different variants of the Sars-CoV-2 virus. The first, symptom-less infection was with the Delta variant, while the second one was Omicron, with cough and fever. Scientists said that this case shows how Omicron can evade immunity from both vaccines and previous infections.
 ======================================
CAPTIONS Spain woman's scary story 2 Covid infections in 20 days Infected by different variants Delta first, then Omicron Shortest re-infection gap case
&nbsp;

<div class="elementToProof">The woman in Spain caught Covid just 12 days after getting a vaccine booster shot; and the second infection followed less than 3 weeks later.</div>

A woman in Spain caught Covid twice, within 20 days, and with different variants.&nbsp;This is being pegged as the shortest re-infection gap recorded since the beginning of the Covid-19 pandemic.
The patient is a healthcare worker, who was fully vaccinated, and had even received a booster dose.&nbsp;Just 12 days after the booster vaccine, on December 20, 2021, the woman tested positive during a staff screening test.&nbsp;She went into isolation for 10 days, but did not develop any symptoms.
Then, on January 10, 2022, twenty days after the first infection, she developed Covid-like symptoms and took another RT-PCR test. The result again came out to be positive.
When the samples were sent for genome sequencing, it emerged that the woman had been infected by two different variants of the Sars-CoV-2 virus.&nbsp;The first, symptom-less infection was with the Delta variant, while the second one was Omicron, with cough and fever.
Scientists said that this case shows how Omicron can evade immunity from both vaccines and previous infections.
Also Watch|&nbsp;<a href="https://www.editorji.com/coronavirus/pandemic-over-omicron-last-variant-who-slams-fake-news-warns-against-covid-laxity-1647769319854" target="_blank">Pandemic over, Omicron last variant? WHO slams fake news, warns against Covid laxity</a>

Even as the Serum Institute of India was being praised in the country for being one of the first vaccine-makers to start providing jabs against Covid-19, the company was facing criticism from foreign media. SII's CEO Adar Poonawalla made the revelation during a conversation with Sanjiv Goenka, chairman, RP-Sanjiv Goenka Group at All India Management Association's (AIMA) 7th National Leadership Conclave.
Poonawalla was asked by Goenka how he dealt with overnight stardom as the Covishield vaccine received approval to become one of the first vaccines to be administered in India. The SII CEO said that while Indian media was fair, foreign media criticised him as it didn't suit the West that "an Indian company had the quality and capability of contributing globally in such an important matter".
Poonawalla said that he received praise and criticism in equal measure at the time, and it was a difficult phase for him. The CEO said that he would be happy to "slowly" fade out of the limelight now.

Foreign media attacked Indian vaccine-maker SII for challenging Western firms' dominance, says Adar Poonawalla on Covid pandemic

Foreign media attacked Indian vaccine-maker SII for challenging Western dominance, says Adar Poonawalla

thumbnail
WHY WESTERN MEDIA ATTACKED S.I.I. FOR SUCCESS
&nbsp;
BYTE
SANJIV GOENKA, CONCLAVE CHAIRMAN &amp; CHAIRMAN, RP-SANJIV GOENKA GROUP https://www.youtube.com/watch?v=hlAxKgoP3hQ
(8:20 - 10:04)
 =========================================
CAPTIONS Serum Institute of India CEO's revelation Foreign media criticised SII: Poonawalla Indian firm's rise didn't suit them: SII CEO Happy to be out of limelight now: SII CEO

<div>Serum Institute of India's CEO Adar Poonawalla said that foreign media criticised India and his company amid Covid for challenging Western firms' dominance.</div>

Even as the Serum Institute of India was being praised in the country for being one of the first vaccine-makers to start providing jabs against Covid-19, the company was facing criticism from foreign media.&nbsp;SII's CEO Adar Poonawalla made the revelation during a conversation with Sanjiv Goenka, chairman, RP-Sanjiv Goenka Group at All India Management Association's (AIMA) 7th&nbsp;National Leadership Conclave.
<a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">Adar&nbsp;Poonawalla</a> was asked by Goenka how he dealt with overnight stardom as the Covishield vaccine received approval to become one of the first vaccines to be administered in India. The SII CEO said that while Indian media was fair, foreign media criticised him as it didn't suit the West that "an Indian company had the quality and capability of contributing globally in such an important matter".
ALSO WATCH:&nbsp;<a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">AIMA 2022: Serum Institute&rsquo;s Adar Poonawalla on building capacity and resilience</a>
Adar Poonawalla said that he received praise and criticism in equal measure at the time, and it was a difficult phase for him. The CEO said that he would be happy to "slowly" fade out of the limelight now.
Also Watch:&nbsp;<a href="https://www.editorji.com/partner/all-india-management-association/aima-conclave-2022-cea-v-anantha-nageswaran-talks-about-building-for-a-better-economy-1649924594182" target="_blank">AIMA 2022: CEA V Anantha Nageswaran talks about building for a better economy</a>

The World Health Organisation has paused the supply of India's first indigenous Covid-19 vaccine, Covaxin, through United Nations agencies. The manufacturer of Covaxin, Bharat Biotech, has reportedly been asked to upgrade facilities and address deficiencies found during an inspection.
The WHO has reportedly asked nations which received consignments of Covaxin to take "appropriate" action. This "appropriate" action has not been described by the WHO in public domain.
Clarifying about the order, the world health body said that Covaxin is effective and safe, but the suspension occurred following an inspection conducted between March 14 and 22, as per reports.
WHO reportedly said Bharat Biotech has "committed to comply by addressing the GMP (good manufacturing practice) deficiencies and is developing a corrective and preventive action plan, for submission to the Drugs Controller General of India (DCGI) and WHO".
Bharat Biotech, while announcing a slowing down of production for facility optimisation, reportedly said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."

Why Covaxin supply was halted by WHO, what Bharat Biotech said | Covid vaccine

&nbsp;
The World Health Organisation has paused the supply of India's first indigenous Covid-19 vaccine, Covaxin, through United Nations agencies. The manufacturer of Covaxin, Bharat Biotech, has reportedly been asked to upgrade facilities and address deficiencies found during an inspection. The WHO has reportedly asked nations which received consignments of Covaxin to take "appropriate" action. This "appropriate" action has not been described by the WHO in public domain. Clarifying about the order, the world health body said that Covaxin is effective and safe, but the suspension occurred following an inspection conducted between March 14 and 22, as per reports. WHO reportedly said Bharat Biotech has&nbsp;"committed to comply by addressing the GMP (good manufacturing practice) deficiencies and is developing a corrective and preventive action plan, for submission to the Drugs Controller General of India (DCGI) and WHO". Bharat Biotech, while announcing a slowing down of production for facility optimisation, reportedly said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."
&nbsp;
 =================================
 CAPTIONS WHO paused Covaxin supply via UN agencies WHO order after inspection of Covaxin factory WHO clarified that Covaxin is safe, effective Covaxin-maker to address 'deficiencies' Bharat Biotech to upgrade facilities
&nbsp;
&nbsp;
&nbsp;

<div style="margin: 0px; padding: 0px; border: 0px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-weight: 400; font-stretch: inherit; font-size: 12pt; line-height: inherit; font-family: Calibri, Arial, Helvetica, sans-serif; vertical-align: baseline; color: #000000; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: #ffffff; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="margin: 0px; padding: 0px; border: 0px; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; font-size: 12pt; line-height: inherit; font-family: inherit; vertical-align: baseline; color: #000000; background-color: #ffffff;">The manufacturer of Covaxin, Bharat Biotech, has reportedly been asked to upgrade facilities and address deficiencies found during an inspection.</div>

The World Health Organisation has paused the supply of India's first indigenous Covid-19 vaccine, Covaxin, through United Nations agencies.&nbsp;The manufacturer of Covaxin, Bharat Biotech, has reportedly been asked to upgrade facilities and address deficiencies found during an inspection.
The WHO has reportedly asked nations which received consignments of Covaxin to take "appropriate" action.&nbsp;This "appropriate" action has not been described by the WHO in public domain. Clarifying about the order, the world health body said that Covaxin is effective and safe, but the suspension occurred following an inspection conducted between March 14 and 22, as per reports.
Also Watch|&nbsp;<a href="https://www.editorji.com/coronavirus/covishield-covaxin-granted-regular-market-approval-what-it-means-1643291432999" target="_blank">Covishield, Covaxin granted regular market approval: what it means</a>
WHO reportedly said Bharat Biotech has&nbsp;"committed to comply by addressing the GMP (good manufacturing practice) deficiencies and is developing a corrective and preventive action plan, for submission to the Drugs Controller General of India (DCGI) and WHO".
Bharat Biotech, while announcing a slowing down of production for facility optimisation, reportedly said, "For the millions who have received Covaxin, the vaccine certificates issued still stand valid as there is no impact on efficacy and safety of the vaccine."

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
The National Technical Advisory Group on Immunisation (NTAGI) has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose.   The recommendation for Covishield is yet to be implemented in the national COVID-19 vaccination programme.
"The latest recommendation of NTAGI is based on recent global scientific evidence derived from programmatic data," PTI quoted an official source as saying. 
"According to it, when the second dose of Covishield is given eight weeks onwards, the antibody response generated is almost similar when administered at an interval of 12 to 16 weeks," the PTI report said. 
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May 13, 2021 extended the gap between the first and second doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.
NTAGI provides guidance and advice to the Union Health Ministry on immunisation services for the effective control of vaccine-preventable diseases in the country.

2nd Covishield dose can be given between 8-16 weeks after first dose: top vaccine body

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, according to reports

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
News agency PTI&nbsp;quoted a source as saying that when the second dose of Covishield is given eight weeks onwards, the antibody&nbsp;response generated is almost similar when administered&nbsp;at an interval of 12 to 16 weeks.&nbsp;
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May&nbsp;13, 2021 extended the gap between the first and second&nbsp;doses&nbsp;of&nbsp;the Covishield&nbsp;vaccine&nbsp;from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, according to reports

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
The National Technical Advisory Group on Immunisation (NTAGI) has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose. &nbsp; The recommendation for Covishield is yet to be implemented in the national COVID-19 vaccination programme.
"The latest recommendation of NTAGI is based on recent global scientific evidence derived from programmatic data," PTI&nbsp;quoted an official source as saying.&nbsp;
"According to it, when the second dose of Covishield is given eight weeks onwards, the antibody&nbsp;response generated is almost similar when administered&nbsp;at an interval of 12 to 16 weeks," the PTI report said.&nbsp;
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May&nbsp;13, 2021 extended the gap between the first and second&nbsp;doses&nbsp;of&nbsp;the Covishield&nbsp;vaccine&nbsp;from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.
NTAGI provides guidance and advice to the Union Health Ministry on immunisation services for the effective control of vaccine-preventable diseases in the country.

The Delhi govt is soon likely to take a decision on reducing the number of Covid-19 vaccination centres in the city following a continued dip in daily vaccinations, the Indian Express has reported.
On Thursday, a total of 17,569 doses of vaccine were administered in Delhi, according to the CoWIN portal, sliding down further from the average 28,000 shots given every day this week.
The newspaper quoted an official as saying that earlier every district reported close to 10,000 shots daily but now they are administering only 1000 shots in a day.
The official also said that a file has already been moved on closing down all vaccination centres in schools. Vaccinations in Delhi schools will now be done only by setting up camps since schools are switching back to offline learning.
Delhi has so far administered 3,18,74,327 Covid-19 vaccination doses

Explained: Why Delhi govt may soon reduce vaccination centres

The Delhi govt is soon likely to take a decision on reducing the number of Covid-19 vaccination centres in the city following a continued dip in daily vaccinations, the Indian Express has reported.
On Thursday, a total of 17,569 doses of vaccine were administered in Delhi, according to the CoWIN portal, sliding down further from the average 28,000 shots given every day this week.
The newspaper quoted an official as saying that earlier every district reported close to 10,000 shots daily but now they are administering only 1000 shots in a day.
The official also said that a file has already been moved on closing down all vaccination centres in schools. Vaccinations in Delhi schools will now be done only by setting up camps since schools are switching back to offline learning.
Delhi has so far administered 3,18,74,327 Covid-19 vaccination doses

On Thursday, a total of 17,569 doses of vaccine were administered in Delhi, according to the CoWIN portal, sliding down further from the average 28,000 shots given every day this week.

The Delhi govt is soon likely to take a decision on reducing the number of Covid-19 vaccination centres in the city following a continued dip in daily vaccinations, the Indian Express has reported.
On Thursday, a total of 17,569 doses of vaccine were administered in Delhi, according to the CoWIN portal, sliding down further from the average 28,000 shots given every day this week.
The newspaper quoted an official as saying that earlier every district reported close to 10,000 shots daily but now they are administering only 1000 shots in a day.
Also watch:&nbsp;<a href="https://www.editorji.com/india-news/covid-spike-in-asian-and-european-countries-centre-says-be-alert-be-prepared-1647497181991">Covid spike in Asian and European countries, Centre says be alert, be prepared</a>
The official also said that a file has already been moved on closing down all vaccination centres in schools. Vaccinations in Delhi schools will now be done only by setting up camps since schools are switching back to offline learning.
Delhi has so far administered 3,18,74,327 Covid-19 vaccination doses

An 85 per cent drop in allocation towards the vaccination program makes it clear that with 76% of adults in India fully vaccinated the free for all vaccine era may be coming to a close. So be ready to buy your own booster?In the budget for the 2021-22 financial year, touted as a health budget, Sitharaman had set aside Rs 35,000 crore for Covid vaccinations this year that figure has dwindled down to just Rs 5000 cr. The reason for the reduction, the document explains, is “lower requirement for vaccination” for Covid.The free vaccine program has boosted the world's largest inoculation drive having delivered 166 crore jabs till the end of Jan. Only about 5% of the 1.67 billion vaccine doses administered nationwide so far have been taken up through private hospitals.But as some experts opine the political cost of not continuing with the free campaign could be viewed as higher than the expenditure required for the campaign.To be able to make the vaccines available for private purchase the govt will have to give the vaccines 'full approval' vs the tag emergency authorisation they have currently. The subject expert committee (SEC) of India's central drug authority has already recommended the promotion in tag to the drug regulator. 

Buy your own booster...the hidden message as govt cuts jab budget by 85% ?

An 85 per cent drop in allocation towards the vaccination program makes it clear that with 76% of adults in India fully vaccinated the free for all vaccine era may be coming to a close. So be ready to buy your own booster?

Get set to buy our own booster

The allocation for medical and public health has gone down from Rs 74,820 crore in the 2021-22 financial year, to Rs 41,011 crore for the 2022-23 fiscal, a reduction of Rs 33,089 cr. T

Centre slashes Covid-19 vaccination budget for 2022-23 by 85%

An 85 per cent drop in allocation towards the vaccination program makes it clear that with 76% of adults in India fully vaccinated the free for all vaccine era may be coming to a close. So be ready to buy your own booster? In the budget for the 2021-22 financial year, touted as a health budget, Sitharaman had&nbsp;set aside&nbsp;Rs 35,000 crore for Covid vaccinations this year that figure has dwindled down to just Rs 5000 cr. The reason for the reduction, the document explains, is &ldquo;lower requirement for vaccination&rdquo; for&nbsp;Covid. The free vaccine program has boosted the world's largest inoculation&nbsp;drive having delivered 166 crore&nbsp;jabs till the end of Jan.&nbsp;Only about 5% of the 1.67 billion vaccine doses administered nationwide so far have been taken up through private hospitals. But as some experts opine the political cost of not continuing with the free campaign could be viewed as higher than the expenditure required for the campaign. Read/Watch Also: <a href="https://www.editorji.com/coronavirus/ej-explains-what-is-regular-market-approval-vs-emergency-use-approval-for-vaccines-1642651443422">Full market approval for jabs - what it means?</a> To be able to make the vaccines available for private purchase the govt will have to give the vaccines 'full approval' vs the tag emergency authorisation they have currently. The subject expert committee (SEC)&nbsp;of India's central drug authority has already recommended the promotion in tag to the drug regulator.&nbsp;

The subject expert committee (SEC) of India's central drug authority has recommended granting regular market approval to Covid vaccines Covishield and Covaxin. The vaccines currently have emergency use authorisation only. Central Drugs Standard Control Organisation (CDSCO)  took to Twitter to confirm that its "SEC has recommended for upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision.What is the difference? An EUA is granted based on review of data by the medical authorities to merely seek it's effectiveness in combating a disease. Only after review of a larger set of data based on a wider set of parameters such as safety, effectiveness and also involves site/facility visits by the medical authorities. So what changes, Why do drug makers want full approval?Under regular (or full) market approval the vaccine would be available even at chemists associated with hospitals and not just centres approved by the government right now. Also a full market approval gives security for production and supply as an EUA can be withdrawn at any point for a particular drug. But withdrawal/recall of an 'approved' drug is not common. Also insurance typically doesn’t pay for products under an EUA so that also weighs on the medication. Do any global vaccines have full approval or are they also on EUAs?On August 23, 2021, the US FDA gave the first full regulatory approval for a Covid vaccine to Pfizer-BioNTech’s Comirnaty for individuals 16 years and older

EJ Explains: What is regular market approval vs emergency use approval for vaccines

Can you soon buy your vaccine from your local hospital's chemist? The expert panel is recommending to  the government that vaccines get upgraded from emergency use to full approval.

EJ Explains: EUA vs full market approval, what's the difference 

An expert panel of India's central drug authority recommended regular market approval to Covid vaccines Covishield and Covaxin.&nbsp;

The subject expert committee (SEC)&nbsp;of India's central drug authority has recommended granting regular market approval to Covid vaccines Covishield and Covaxin. The vaccines currently have emergency use authorisation only.&nbsp; Central Drugs Standard Control Organisation (CDSCO)&nbsp; took to Twitter to confirm that its "SEC has recommended for upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision. What is the&nbsp;difference?&nbsp; An EUA&nbsp;is granted based on review of data by the medical authorities to merely seek it's effectiveness in combating a disease.&nbsp; Only after review of a larger set of data based on a wider set of parameters such as safety, effectiveness and also involves site/facility visits by the medical authorities.&nbsp; So what changes, Why do drug makers want full approval? Under&nbsp;regular (or full) market approval the vaccine would be available even at chemists associated with hospitals and not just centres approved by the government right now.&nbsp; Which means that if you wanted a booster shot you would be able to get the vaccine from a hospital chemist and have your doctor administer it for you. Also a full market approval gives security for production and supply as an EUA&nbsp;can be withdrawn at any point for a particular drug. But withdrawal/recall of an 'approved' drug is not common.&nbsp; Also insurance typically doesn&rsquo;t pay for products under an EUA&nbsp;so that also weighs on the medication.&nbsp; Do any global vaccines have full approval or are they also on EUAs? On August 23, 2021, the US FDA gave the first full regulatory approval for a Covid vaccine to Pfizer-BioNTech&rsquo;s Comirnaty for individuals 16 years and older

Greek tennis sensation Stefanos Tsitsipas has ripped apart Novak Djokovic's bid to play the Australian Open without vaccination after wining a legal court battle to overturn the decision of cancellation of his visa. 
Tsitsipas directly questioned Djokovic's decision to land in Australia without getting vaccinated which is against the rules set by the government. 
The World Number 4 said, "Not having to follow the protocols that they gave me, which, it takes a lot of daring to do I think, and putting a Grand Slam kind of at risk". 
The 2021 French Open finalist in fact questioned why the Australian Government or Tennis Australia is ready to make exceptions for a tennis player when the rest are following the mandate. He said, "It kind of seems like not everyone is playing by the rules of how Tennis Australia or some governments have been putting things, and each single one of, a very small majority, of that percentage, choose to follow their own way, which, kind of makes the rest, the majority, look like, I don't know, like they're all fools or something".
The Australian Open draw which was meant to take place on Thursday has been delayed by Tennis Australia as they await the final decision from the government over Novak Djokovic's deportation. 

Stefanos Tsitsipas rips apart Novak Djokovic's bid to play Australian Open without vaccination

The Australian Open has named Novak Djokovic as the top seed in the Men's singles draw despite still waiting for the official word on his deportation from the government. 

Stefanos Tsitsipas rips apart Djokovic's bid to play Australian Open without vaccination

Greek tennis sensation&nbsp;Stefanos Tsitsipas&nbsp;has ripped apart Novak&nbsp;Djokovic's&nbsp;bid to play the Australian Open without vaccination after wining a legal court battle to overturn the decision of cancellation of his visa.&nbsp;
Tsitsipas&nbsp;directly questioned Djokovic's&nbsp;decision to land in Australia without getting vaccinated which is against the rules set by the government.&nbsp;
The World Number 4 said, "Not having to follow the protocols that they gave me, which, it takes a lot of daring to do I think, and putting a Grand Slam kind of at risk".&nbsp;
The 2021 French Open finalist in fact questioned why the Australian Government or Tennis Australia is ready to make exceptions for a tennis player when the rest are following the mandate. He said, "It kind of seems like not everyone is playing by the rules of how Tennis Australia or some governments have been putting things, and each single one of, a very small majority, of that percentage, choose to follow their own way, which, kind of makes the rest, the majority, look like, I don't know, like they're all fools or something".
The Australian Open has named Novak&nbsp;Djokovic&nbsp;as the top seed in the Men's singles draw despite still waiting for the official word on his deportation from the government.&nbsp;

World number 4&nbsp;Stefanos Tsitsipas&nbsp;questions Novak&nbsp;Djokovic's&nbsp;vaccine inhibition, calls it a threat to the Grand Slam

Greek tennis sensation&nbsp;Stefanos Tsitsipas&nbsp;has ripped apart Novak&nbsp;Djokovic's&nbsp;bid to play the Australian Open without vaccination after wining a legal court battle to overturn the decision of cancellation of his visa.&nbsp; Also Read <a href="https://www.editorji.com/sports-news/others-sports/india-open-7-players-including-kidambi-srikanth-test-positive-for-covid-19-1642044763579">India Open: 7 players including Kidambi Srikanth test positive for Covid-19 </a>
Tsitsipas&nbsp;directly questioned Djokovic's&nbsp;decision to land in Australia without getting vaccinated which is against the rules set by the government.&nbsp;
The World Number 4 said, "Not having to follow the protocols that they gave me, which, it takes a lot of daring to do I think, and putting a Grand Slam kind of at risk".&nbsp;
The 2021 French Open finalist in fact questioned why the Australian Government or Tennis Australia is ready to make exceptions for a tennis player when the rest are following the mandate. He said, "It kind of seems like not everyone is playing by the rules of how Tennis Australia or some governments have been putting things, and each single one of, a very small majority, of that percentage, choose to follow their own way, which, kind of makes the rest, the majority, look like, I don't know, like they're all fools or something".
The Australian Open has named Novak&nbsp;Djokovic&nbsp;as the top seed in the Men's singles draw despite still waiting for the official word on his deportation from the government.&nbsp;

vaccine

Categories